Albumin is found in blood plasma and is the most abundant protein. It aids a wide range of functions such as fatty acids and transportation of hormones and maintains oncotic pressure. A variety of serum albumin is widely used for clinical applications.
Bovine serum albumin and human serum albumin and are obtained from bovine plasma and human plasma, respectively. Whereas, the recipient is manufactured by recreational techniques in albumin bacteria and yeast strains. Intensely, it helps restore blood volume due to changing lost fluid and burning, trauma, surgery, or infection and liver diseases.
Key Growth Drivers and Opportunities
Rising Cases of Liver disease: The report published by Centers for Disease Control and Prevention, numbers of people diagnosed suffering from liver disease were 4.9 million in the U.S. This indicates the requirement of people suffering from a state where their livers are not able to produce albumin anymore. This is estimated to collect sufficient demand for the product, due to its important nature in major physical functions such as the transport of essential minerals, vitamins and hormones.
Challenges
The alternative to increasing prevalence’s of hypoalbuminemia and hypovolemia worldwide, certain factors such as lower availability of therapeutic products and strict government norms are hampering the adoption of albumin. Further, stringent government regulation imposed on producing therapeutic applications is one of the major restraining factors for the target market. For instance, the government of U.S., ensures that the plasma collected and distributes undergoes the international standards of safety, quality, and potency.
Innovation and Expansion
Grifols Sees Albumin Trial Success in Liver Disease
In May 2025, Griffols revealed to encourage topline results from its Phasiii PRECIOSA test, which evaluates albutin (human serum albumin) in patients with disintegrated cirrhosis and ascites. Data showed improvement in transplant-free survival in 3 months, placing to offer full conclusions in EASL.
Conclusions strengthen the therapeutic capacity of long -term albumin treatment in the management of advanced liver conditions. This development can support future regulatory submissions and broad clinical adoption throughout Europe.
Efruxifermin Shows Significant Fibrosis Reversal in MASH Cirrhosis Trial
In May 2025, Efruxifermin- Statistically significant 29% of patients with mash cirrhosis with steps 2B symmetry test-muravaji of a FGF21 analog received ≥1-phase fibrosis improvement (11% for Placebo). The results presented in EASL also showed benefits in histologic liver markers and metabolic profiles.
Twelve months after the plant Development Agreement (PDA) is signed, the captive solar plant will be put into service. For TP Solar, TPREL has formed TP Govardhan Creatives Limited, a specialist organization charged with the construction, management, and maintenance of this plant.
Inventive Sparks, Expanding Markets
The prominent player operating in the albumin market includes Grifols S.A., China Biologic Products Inc., Ventria Bioscience, Shire Plc, among others. Prominent players in the market are dominating and producing innovative products.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.